Tenet Healthcare Corp. reported first‑quarter 2026 results that beat earnings expectations while falling short of revenue forecasts. Adjusted earnings per share rose to $4.82, surpassing the consensus estimate of $4.21 by $0.61, a 14.4% beat. Net operating revenue totaled $5.368 billion, slightly below the $5.39 billion consensus, a miss of $20 million or 0.4%.
Revenue growth was driven by a 10.6% increase in Ambulatory Care revenue to $1.32 billion, powered by strong same‑facility growth and new facility acquisitions. Hospital Operations revenue grew modestly 0.5% to $4.05 billion, but adjusted admissions rose only 0.6% while net revenue per adjusted admission fell 1.5% due to a less favorable payer mix. The company’s adjusted EBITDA stood at $1.162 billion, essentially flat year‑over‑year at $1.163 billion, reflecting a margin contraction to 21.6% from 22.3% in Q1 2025.
Operating cash flow surged to $1.641 billion, up from $815 million a year earlier, and the company repurchased 1.35 million shares for $318 million during the quarter. The early conclusion of the Conifer Health Solutions contract with CommonSpirit contributed $413 million in revenue and $314 million after‑tax, along with an approximate $40 million favorable non‑recurring pre‑tax impact, reinforcing Tenet’s cash‑flow position and control of its revenue‑cycle management business.
Management raised its full‑year 2026 adjusted EPS guidance to $16.38–$18.68 per share, up from $16.19–$18.47, and reaffirmed revenue guidance of $21.5 billion–$22.3 billion. "We delivered strong results in both the Ambulatory and Hospital segments in the first quarter of 2026, characterized by disciplined operations and strong free cash flow. We continue to support our physician partners to drive innovation in patient care as we execute on our high acuity strategy and grow our businesses both organically and inorganically," said Chairman and CEO Saum Sutaria.
The results were met with a muted market reaction. Investors focused on the revenue miss and flat year‑over‑year EBITDA, which tempered enthusiasm for the EPS beat. Analysts noted that the company’s margin contraction was largely driven by the unfavorable payer mix in the Hospital segment, offsetting gains in Ambulatory Care. Despite these headwinds, the raised guidance signals management’s confidence in sustaining growth and maintaining profitability amid ongoing payer‑mix challenges.
Prior‑period comparisons underscore the company’s trajectory: Q1 2025 net operating revenue was $5.223 billion, net income to common shareholders $406 million, and adjusted diluted EPS $4.36; Q4 2025 revenue was $5.527 billion, adjusted EPS $4.70, and adjusted EBITDA $1.183 billion. The current quarter’s figures show accelerated Ambulatory Care growth, modest Hospital revenue gains, and a slight decline in overall margin, painting a nuanced picture of performance and strategic focus.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.